Epredia's SlideMate™ Laser Printer Earns Innovative Recognition

Epredia's Remarkable Achievement with SlideMate™ Laser Printer

Epredia, a global leader in precision cancer diagnostics, recently earned an Innovative Technology Designation from Vizient for its innovative SlideMate™ Laser slide printer, a notable milestone in enhancing laboratory efficiency and sample traceability. This recognition is significant within the healthcare sector and showcases the efforts of Epredia in developing technologies that elevate patient care.

Innovative Technology Designation Explained

Each year, healthcare experts evaluate select products aimed at enhancing clinical care, patient safety, and operational efficiency for healthcare organizations. The Innovative Technology designation is a way to highlight previously contracted products that exhibit promising potential in impacting patient care effectively. Epredia's SlideMate Laser was recently showcased at the Vizient Innovative Technology Exchange, further emphasizing its relevance in modern healthcare settings.

Benefits of the SlideMate™ Laser Printer

The SlideMate portfolio is integral to cancer diagnostics, playing a crucial role in identifying and tracking tissue samples. Designed specifically for clinical laboratories, the SlideMate Laser provides impressively high-resolution, 600-dpi laser printing on microscope slides, allowing laboratories to incorporate substantial identifying information directly on the slides used by pathologists.

Enhanced Sample Traceability and Efficiency

One of the standout features of the SlideMate Laser printer is its ability to embed up to 50 characters in a barcode on each slide. This surpasses the limitations of traditional thermal transfer and inkjet technologies, which only support 23 characters, thus significantly improving patient sample tracking capabilities.

In addition to optimizing traceability, the SlideMate Laser printer enhances laboratory operations by streamlining slide movements and reducing operational downtime compared to conventional printers. This advantage is complemented by the elimination of costs associated with purchasing ink, bulbs, or tape, resulting in lower overall operational expenses. The printer also supports both on-demand and batch printing, ensuring flexibility across various laboratory workflows.

Commitment to Cancer Diagnostics

SlideMate Laser is a notable extension of Epredia's extensive array of precision cancer diagnostic solutions. The company emphasizes a comprehensive end-to-end laboratory workflow, supported by specialized slides tailored for use with the SlideMate Laser. This thoughtful design streamlines the transition to precision laser printing for laboratories.

Leadership Remarks

Steven Lynum, President of Epredia, expressed pride in achieving this designation, recognizing it as a testament to their mission in transforming anatomical pathology through greater efficiency in cancer diagnostics. He emphasized the company's ongoing commitment to enhancing patient outcomes by enabling pathologists to operate at their highest capacity.

Industry Recognition

Kelly Flaharty, a senior director at Vizient, praised Epredia for this peer-desired recognition, affirming the SlideMate Laser's potential to profoundly impact the healthcare industry. This designation reinforces Epredia’s contributions to the advancement of healthcare technology.

About Epredia and PHC Holdings Corporation

Epredia operates as a leading entity in anatomical pathology, providing a wide range of solutions aimed at improving precision cancer diagnostics. With esteemed brands such as Erie Scientific and Richard-Allan Scientific under its wing, Epredia was established post the acquisition of Thermo Fisher Scientific's Anatomical Pathology division by PHC Holdings in 2019. The company boasts diverse manufacturing operations spanning across multiple countries, dedicated to enhancing cancer diagnostics globally.

PHC Holdings Corporation, listed under TSE 6523, is a global healthcare entity with the goal of positively influencing societal health through impactful healthcare solutions. It encompasses a variety of subsidiaries, including Ascensia Diabetes Care and LSI Medience Corporation, that collectively aim to provide excellent healthcare innovations and services across the globe.

Frequently Asked Questions

What is the SlideMate™ Laser printer?

The SlideMate™ Laser printer by Epredia is a high-resolution printing device designed for cancer diagnostics, enabling improved traceability and efficiency in laboratories.

Who awarded the Innovative Technology Designation?

The Innovative Technology Designation was awarded by Vizient, a leader in healthcare performance improvement focused on enhancing clinical care and safety.

Why is the SlideMate™ Laser printer significant?

This printer is significant because it allows embedding more identifying information on slides, improving sample tracking and laboratory efficiency.

What organizations evaluate technologies for Vizient?

Healthcare experts serving on Vizient’s provider-led councils assess technologies for their potential in improving clinical practices and operational efficiencies.

What is Epredia's mission?

Epredia’s mission is to enhance cancer diagnostics and improve patient outcomes through innovative and comprehensive solutions in pathology.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.